Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Full story
Read the full story at CNBC Europe ↗
Continue reading this story on CNBC Europe, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
